Christian T. Ruff, MD, MPH is the Director of General Cardiology in the Cardiovascular Division at Brigham and Women's Hospital.
Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial
Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.
Read More
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban
Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.